The MR analysis provided robust evidence for an association between lowering LDL cholesterol through two drug targets and acne vulgaris, with PCSK9 showing an odds ratio (OR) of 1.782 (95%CI: 1.129–2.812, p = 0.013) and LDL receptor (LDLR) with an OR of 1.581 (95%CI: 1.071–2.334, p = 0.021). The gene discussed is LDLR; the disease is acne.